Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Lowered by Wall Street Zen

Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

A number of other analysts have also weighed in on COLL. Piper Sandler restated a “neutral” rating and issued a $43.00 target price (down from $45.00) on shares of Collegium Pharmaceutical in a research report on Friday. Needham & Company LLC dropped their price target on Collegium Pharmaceutical from $56.00 to $46.00 and set a “buy” rating for the company in a research note on Thursday. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Truist Financial raised Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $52.60.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $29.47 on Friday. The company has a market cap of $959.54 million, a price-to-earnings ratio of 23.77 and a beta of 0.73. The company has a current ratio of 1.03, a quick ratio of 0.84 and a debt-to-equity ratio of 3.32. Collegium Pharmaceutical has a 12 month low of $28.01 and a 12 month high of $50.79. The stock has a 50-day moving average price of $34.78 and a two-hundred day moving average price of $37.01.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $199.88 million for the quarter, compared to the consensus estimate of $199.62 million. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the company posted $1.68 EPS. As a group, analysts forecast that Collegium Pharmaceutical will post 6.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Collegium Pharmaceutical

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in Collegium Pharmaceutical during the 2nd quarter valued at approximately $196,972,000. Deutsche Bank AG acquired a new position in shares of Collegium Pharmaceutical in the 2nd quarter worth approximately $1,270,000. Bank of New York Mellon Corp bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at $8,506,000. State of Wyoming bought a new stake in shares of Collegium Pharmaceutical in the 2nd quarter valued at $218,000. Finally, One Wealth Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical during the second quarter worth $310,000.

Collegium Pharmaceutical News Roundup

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Second-quarter adjusted EPS was $1.92, above analyst expectations of approximately $1.72, while revenue increased 6.3% year over year to $199.9 million. Adjusted EBITDA rose 8% to $113.8 million and operating cash flow was $71.3 million. Collegium Pharmaceutical Q2 Earnings Beat
• Positive Sentiment: The ADHD portfolio showed momentum: JORNAY PM revenue climbed 41% to $46.1 million, and the completed AZSTARYS acquisition contributed $12.9 million in partial-quarter revenue. Collegium raised its full-year AZSTARYS revenue outlook to $65 million-$75 million from $60 million-$70 million, potentially supporting longer-term growth. Collegium Q2 2026 Results
• Neutral Sentiment: Piper Sandler reaffirmed its “neutral” rating but lowered its price target to $43 from $45. Needham retained a “buy” rating while cutting its target to $46 from $56, reflecting continued upside but greater near-term caution. Analyst Price Target Updates
• Negative Sentiment: Collegium reduced full-year product-revenue guidance to $825 million-$855 million from $865 million-$895 million and lowered adjusted EBITDA guidance to $445 million-$470 million from $475 million-$500 million. The company cited lower pricing and weaker-than-expected authorized-generic Nucynta revenue.
• Negative Sentiment: The pain portfolio declined 9% year over year to $140.9 million; Nucynta revenue fell 24% and Xtampza ER revenue dropped 14%. GAAP results also shifted to a $15.1 million net loss from $12.0 million of net income, while operating expenses increased 45%, adding pressure to profitability. Collegium Sales and Guidance Report

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.